Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Mar;259(3):474-81.
doi: 10.1007/s00415-011-6204-9. Epub 2011 Aug 7.

A retrospective clinical study of the treatment of slow-channel congenital myasthenic syndrome

Amina Chaouch  1 , Juliane S Müller, Velina Guergueltcheva, Marina Dusl, Ulrike Schara, Vidosava Rakocević-Stojanović, Christopher Lindberg, Rosana H Scola, Lineu C Werneck, Jaume Colomer, Andres Nascimento, Juan J Vilchez, Nuria Muelas, Zohar Argov, Angela Abicht, Hanns Lochmüller
Affiliations

A retrospective clinical study of the treatment of slow-channel congenital myasthenic syndrome

Amina Chaouch et al. J Neurol. 2012 Mar.

Abstract

Slow-channel congenital myasthenic syndrome (CMS) is a rare subtype of CMS caused by dominant "gain of function" mutations in the acetylcholine receptor. Clinically, the cervical and forearm extensor muscles seem to be preferentially weaker; and conventional treatment with anticholinesterases fails to improve symptoms. In contrast, open channel blockers such as fluoxetine and quinidine have been shown to be of benefit. The objectives of our study were to provide further insight into the clinical features of slow-channel CMS and evaluate response to recommended therapy. We carried out a retrospective clinical follow up study of 15 slow-channel CMS patients referred to the Munich CMS Centre. Detailed clinical data were collected by clinicians involved in the care of each patient, with a particular focus on response and tolerability to recommended therapy. Patients varied widely as regard onset of symptoms, severity of disease and mutations involved. Patients received up to four different medications and some had none. Our results strengthen previous reported findings in terms of clinical phenotype variability and the poor response to pyridostigmine. Although treatment with fluoxetine was beneficial in most patients, a number of our patients suffered significant adverse effects that hindered optimum dose titration or led to treatment cessation. Slow-channel CMS is rare and exhibits distinct clinical and genetic characteristics. Our study suggests that fluoxetine, despite being effective in most patients, can be associated with significant side effects, thus reducing treatment effectiveness in clinical practice.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Neuromuscul Disord. 2006 May;16(5):329-33 - PubMed
    1. J Neurol Neurosurg Psychiatry. 2010 Sep;81(9):973-7 - PubMed
    1. Ann Neurol. 1982 Jun;11(6):553-69 - PubMed
    1. Neurotherapeutics. 2007 Apr;4(2):252-7 - PubMed
    1. Expert Rev Mol Med. 2007 Aug 09;9(22):1-20 - PubMed

Publication types

LinkOut - more resources